Camptothecin in sterically stabilized phospholipid nano-micelles: A novel solvent pH change solubilization method

Journal of Nanoscience and Nanotechnology

Volumn 6, Issue 9-10, 2006, Pages 2996-3000

  Koo, Otilia M Y ^a   Rubinstein, Israel ^a,b   Onyuksel, Hayat ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Camptothecin; Nano Micelles; PEGylated Phospholipids; pH Change; Solubilization

Indexed keywords

CAMPTOTHECIN (CPT); INCUBATION; MICROVASCULATURE; NANOCARRIERS;

DRUG DOSAGE; ENZYME INHIBITION; HYDROPHOBICITY; MICELLES; NANOSTRUCTURED MATERIALS; PH EFFECTS; PHARMACOKINETICS; PHOSPHOLIPIDS; POLYETHYLENE GLYCOLS; TOXICITY; TUMORS;

DRUG PRODUCTS;

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG CARRIER; NANOMATERIAL; PHOSPHOLIPID; SOLVENT;

ARTICLE; CHEMISTRY; DIFFUSION; DRUG STABILITY; ISOMERISM; MICELLE; PH; SOLUBILITY;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DIFFUSION; DRUG CARRIERS; DRUG STABILITY; HYDROGEN-ION CONCENTRATION; ISOMERISM; MICELLES; NANOSTRUCTURES; PHOSPHOLIPIDS; SOLUBILITY; SOLVENTS;

EID: 33750065726     PISSN: 15334880     EISSN: None     Source Type: Journal    
DOI: 10.1166/jnn.2006.460     Document Type: Conference Paper

References (22)

1. M. K. Clements, S. Wasi, and S. S. Daoud, Anticancer Drugs 7, 851 (1996).
2. E. A. Natelson, B. C. Giovanella, C. F. Verschraegen, K. M. Fehir, P. D. De Ipolyi, N. Harris, and J. S. Stehlin, Ann. N. Y. Acad. Sci. 803, 224 (1996).
3. N. H. Oberlies and D. J. Kroll, J. Nat. Prod. 67, 129 (2004).
4. R. Garcia-Carbonero and J. G. Supko, Clin Cancer Res. 8, 641 (2002).
5. U. Schaeppi, R. W. Fleischman, and D. A. Cooney, Cancer Chemother. Rep 3, 25 (1974).
6. C. L. Erickson-Miller, R. D. May, J. Tomaszewski, B. Osborn, M. J. Murphy, J. G. Page, and R. E. Parchment, Cancer Chemother Pharmacol. 39, 467 (1997).
7. O. Koo, I. Rubinstein, and H. Onyuksel, Nanomedicine. 1, 77 (2005).
8. A. N. Lukyanov, Z. Gao, L. Mazzola, and V. P. Torchilin, Pharm Res. 19, 1424 (2002).
9. S. H. Jang, M. G. Wientjes, D. Lu, and J. L. Au, Pharm Res. 20, 1337 (2003).
10. L. Arleth, B. Ashok, H. Onyuksel, P. Thiyagarajan, J. Jacob, and R. P. Hjelm, Langmuir 21, 3279 (2005).
11. B. Ashok, L. Arleth, R. P. Hjelm, I. Rubinstein, and H. Onyuksel, J. Pharm. Sci. 93, 2476 (2004).
12. P. K. Working and A. D. Dayan, Hum Exp Toxicol. 15, 751 (1996).
13. O. Garbuzenko, S. Zalipsky, M. Qazen, and Y. Barenholz, Langmuir 21, 2560 (2005).
14. M. C. Woodle, M. S. Newman, and J. A. Cohen, J. Drug. Target. 2, 397 (1994).
15. B. E. Rabinow, Nat. Rev. Drug. Discov. 3, 785 (2004).
16. J. H. Beijnen, H. Rosing, W. W. ten Bokkel Huinink, and H. M. Pinedo, J. Chromatogr. 617, 111 (1993).
17. R. Cortesi, E. Esposito, A. Maietti, E. Menegatti, and N. C., Int. J. Pharm. 159, 95 (1997).
18. T. G. Burke, A. K. Mishra, M. C. Wani, and M. E. Wall, Biochemistry. 32, 5352 (1993).
19. D. Needham, T. J. McIntosh, and D. D. Lasic, Biochim. Biophys. Acta. 1108, 40 (1992).
20. R. Barreiro-Iglesias, L. Bromberg, M. Temchenko, T. A. Hatton, A. Concheiro, and C. Alvarez-Lorenzo, J. Control. Rel. 97, 537 (2004).
21. T. X. Xiang and B. D. Anderson, Pharm Res. 19, 1215 (2002).
22. T. G. Burke, A. E. Staubus, and A. K. Mishra, J. Amer. Chem. Soc. 114, 8318 (1992).